The treatment combines buprenorphine, a partial-opioid agonist, with naloxone, an opioid antagonist.
Mental health, education level, and recent drug use may be associated with duration of treatment with extended-release naltrexone for opioid dependence.
Buprenorphine maintenance treatment for opioid dependence may result in hyperalgesia and prevent morphine-associated antinociception.
A longer duration of extended-release naltrexone treatment in individuals with opioid dependence was associated with improved outcomes and reduced rates of relapse.
Identification of Active-State Kappa-Opioid Receptor Crystal Structure May Facilitate the Design of Improved AnalgesicsJanuary 18, 2018
Elucidation of the crystal structure of κ-opioid receptors in their active state may facilitate the design of optimized analgesics, devoid of psychoactive effects and of addictive properties.
Compared with buprenorphine-naloxone, use of extended-release naltrexone maintained abstinence from heroin and other illicit substances at a similar rate.
Changes in several measures of pain in patients suspected of opioid-induced hyperalgesia were observed after transitioning from opioids to buprenorphine.
Doctors who limit the supply of opioids they prescribe to 3 days or less may help patients reduce their risk of dependence and addiction.
An 8-day detoxification process using low-dose oral naltrexone showed superior efficacy to the standard 15-day approach that uses an agonist taper leading to induction with extended-release naltrexone
Buprenorphine implants could help improve relapse prevention in patients who are currently maintaining abstinence with sublingual buprenorphine
Improved delivery method for buprenorphine
Lower rate of relapse compared with usual treatment in trial involving criminal justice offenders.
Clinical Pain Advisor Articles
- Rapid Fentanyl Test Strips Accepted by Young Adult Drug Users
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- Central Sensitization in Greater Trochanteric Pain Syndrome
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Long Wait Times Between Referral and Interdisciplinary Pediatric Chronic Pain Evaluation